To include your compound in the COVID-19 Resource Center, submit it here.

Lyxumia lixisenatide: Phase III data

Top-line data from the double-blind, international Phase III GetGoal-L trial in 495 Type II diabetics inadequately controlled with basal insulin showed that once-daily 20

Read the full 244 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE